Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.31 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2758651 | 0.91 | CTSK (0.37) | CTSKALDH1A1NPC1SMN1; SMN2LMNA | |
| SCHEMBL2721780 | 0.89 | CTSK (0.39) | CTSKALDH1A1NPC1SMN1; SMN2LMNA | |
| SCHEMBL211840 | 0.89 | CTSK (0.39) | CTSKALDH1A1NPC1SMN1; SMN2LMNA | |
| SCHEMBL211353 | 0.89 | CTSK (0.39) | CTSKALDH1A1NPC1SMN1; SMN2LMNA | |
| SCHEMBL2721705 | 0.89 | CTSK (0.40) | CTSKALDH1A1NPC1SMN1; SMN2LMNA | |
| SCHEMBL4353514 | 0.88 | CTSK (0.39) | CTSKALDH1A1NPC1SMN1; SMN2LMNA | |
| SCHEMBL2723918 | 0.88 | CTSK (0.39) | CTSKALDH1A1NPC1SMN1; SMN2LMNA | |
| SCHEMBL211468 | 0.87 | CTSK (0.37) | CTSKALDH1A1NPC1SMN1; SMN2LMNA | |
| SCHEMBL209768 | 0.87 | CTSK (0.38) | CTSKALDH1A1NPC1SMN1; SMN2LMNA | |
| SCHEMBL212342 | 0.87 | CTSK (0.39) | CTSKALDH1A1NPC1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088793-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | CTSK 1455/4885ALDH1A1 1710/4885NPC1 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.